Granite Investment Partners LLC Lowers Stake in Guardant Health, Inc. $GH

Granite Investment Partners LLC lessened its stake in Guardant Health, Inc. (NASDAQ:GH) by 52.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 185,301 shares of the company’s stock after selling 201,565 shares during the period. Granite Investment Partners LLC owned 0.15% of Guardant Health worth $11,578,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in GH. Norges Bank purchased a new position in shares of Guardant Health during the second quarter worth approximately $64,136,000. Franklin Resources Inc. grew its stake in Guardant Health by 78.2% in the second quarter. Franklin Resources Inc. now owns 2,319,947 shares of the company’s stock worth $120,730,000 after purchasing an additional 1,018,144 shares in the last quarter. Invesco Ltd. increased its holdings in Guardant Health by 27.3% during the 2nd quarter. Invesco Ltd. now owns 3,558,501 shares of the company’s stock worth $185,184,000 after purchasing an additional 763,834 shares during the period. Jennison Associates LLC bought a new stake in Guardant Health during the 2nd quarter valued at $37,233,000. Finally, Nikko Asset Management Americas Inc. lifted its holdings in shares of Guardant Health by 49.6% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 2,030,428 shares of the company’s stock worth $105,623,000 after buying an additional 673,438 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Guardant Health

In other Guardant Health news, CFO Michael Brian Bell sold 80,362 shares of the firm’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $103.14, for a total value of $8,288,536.68. Following the completion of the sale, the chief financial officer owned 28,052 shares of the company’s stock, valued at approximately $2,893,283.28. This trade represents a 74.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Amirali Talasaz sold 100,000 shares of the business’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $105.05, for a total value of $10,505,000.00. Following the sale, the chief executive officer owned 168,223 shares in the company, valued at $17,671,826.15. The trade was a 37.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 434,511 shares of company stock worth $45,580,887 over the last ninety days. Corporate insiders own 6.10% of the company’s stock.

More Guardant Health News

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Multiple brokerages raised price targets and maintained buy/overweight ratings (Leerink to $180, JPMorgan to $130, Wells Fargo to $125, BTIG to $145, Canaccord to $135), signaling analyst confidence in upside from current levels. Analyst Raises Coverage
• Positive Sentiment: Q4 revenue beat and strong growth: Guardant reported $281.3M in Q4 revenue, +39% YoY and above consensus; management issued FY2026 revenue guidance around $1.3B, above Street expectations — a growth signal for core oncology testing. Press Release
• Positive Sentiment: Research coverage expansion: Robert W. Baird initiated coverage, which can broaden institutional interest and trading liquidity. Coverage Start
• Neutral Sentiment: Conference call and transcript available — provides detail on cadence of test volume, reimbursement progress and product roadmap; useful for digging into guidance assumptions. Earnings Transcript
• Neutral Sentiment: Market materials (slide deck, press release) posted for investors to verify segment trends and margin assumptions. Slide Deck / Press Release
• Neutral Sentiment: Short-interest data flagged a “significant increase” entry but shows 0 shares / NaN in the feed — the published data appears inconsistent, so short-interest impact is unclear. Short Interest Note
• Negative Sentiment: EPS miss: GAAP loss of ($0.50) vs. consensus (~($0.43)), which disappointed some investors despite revenue upside and may have pressured the stock near the close. Earnings Reaction
• Negative Sentiment: Management left EPS guidance effectively blank in the release (revenue guidance given but no numeric EPS target), which can create uncertainty around near-term profitability expectations. Guidance Details

Guardant Health Stock Down 3.1%

NASDAQ:GH opened at $103.10 on Monday. The stock has a market capitalization of $13.52 billion, a price-to-earnings ratio of -31.15 and a beta of 1.63. Guardant Health, Inc. has a 52 week low of $34.88 and a 52 week high of $120.74. The firm has a 50 day moving average of $106.69 and a 200 day moving average of $86.51.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The firm had revenue of $281.27 million during the quarter, compared to analyst estimates of $269.74 million. During the same quarter in the previous year, the firm posted ($0.62) earnings per share. The company’s quarterly revenue was up 39.4% on a year-over-year basis. As a group, analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on GH shares. TD Cowen raised their price target on Guardant Health from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Friday. Guggenheim raised their target price on shares of Guardant Health from $115.00 to $135.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Barclays reaffirmed an “overweight” rating and issued a $130.00 price target on shares of Guardant Health in a research report on Friday. Morgan Stanley lifted their price objective on shares of Guardant Health from $105.00 to $130.00 and gave the company an “overweight” rating in a report on Monday, December 1st. Finally, Robert W. Baird initiated coverage on Guardant Health in a report on Tuesday, February 17th. They set an “outperform” rating and a $120.00 target price for the company. Twenty-one investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $117.43.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.